We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
Brands / NEURAXPHARM

IS GERMANY’S LEADING CNS GENERIC PHARMACEUTICAL COMPANY

specialised in standard and differentiated generics and originals

Neuraxpharm

which has a portfolio of over 100 predominantly differentiated products to serve the needs of CNS patients, has been a trusted brand for neurologists, psychiatrists, pharmacists and patients for over three decades

neuraxpharm is focused on providing their patients with high-quality, well-tolerated, easy-to-dose, affordable medicinal products, to ensure that the treatment provided is as personal and successful as possible.

neuraxpharm invests principally in the development of pharmaceutical technologies; in improving existing pharmaceutical forms and in upgrading new products. In some cases, new patient-friendly products and formulations are developed at the request of, and in close consultation with, medical specialists.

Headquartered in Düsseldorf (Germany)
neuraxpharm is the Top-Selling German
specialty generic players with a focus on CNS products

Focus

Pipeline with mix of
  • Differentiated products
  • Standard generics
  • Niche products
  • Originals

Portfolio

  • Strong product portfolio in specialty fields: neurology and psychiatry
  • Broad and comprehensive market portfolio with more than 100 molecules in approx. 400 pharmaceutical forms
  • #1 position in antidepressants, antipsychotics and anti-Parkinson agents


43%
Antidepressants
28%
Antipsychotics
19%
Antiparkinson
10%
Antiepileptics

Sales driver

  • Almost full coverage of psychiatrists & neurologists (office based) and KOLs (psychiatrists) for originals
  • Well-established and highly respected partner for specialist doctors, pharmacists and patients
  • Advisory board with 6 KOLs
  • Social responsibility through a dedicated CNS foundation, providing support to the targeted patient/care community
    https://www.neuraxfoundation.de/
  • Educational service, own publications, participation in all relevant psychiatry, neurology and medical services congresses

neuraxpharm
holds a 17%

market share and #1 position, sustained over the last 6 years